Company profile
Twist Bioscience Corporation
NASDAQ: TWST · Healthcare · Medical - Diagnostics & Research
#233 of 1,422 Healthcare companies by revenue67th-percentile growth
EA Score
70BFH 68DQ 71GM 72SS 72
v0.1 · 65/100 weight · provisional
↑ filing timeliness, market scale · ↓ listing tenure, disclosure history
Methodology →Revenue TTM
$409.5M
Rev growth YoY (TTM)
+17.8%
Net income (FY)
-$77.7M
Employees
979
as of 2026-08-07
Market cap
$6.8B
as of 2026-08-07
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$376.6M$376.6M2025
Net income-$77.7M-$77.7M2025
Operating income-$136.3M-$136.3M2025
Total assets$641.9M$641.9M2025
Liabilities$168.9M$168.9M2025
Equity$473.0M$473.0M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Ngs Tools55%
Synthetic Genes30%
Antibody Discovery6%
Oligo Pools5%
Dna And Biopharma Libraries3%
By geography
Americas60%
EMEA33%
Asia Pacific7%
The read
What is Twist Bioscience Corporation’s revenue?
Twist Bioscience Corporation booked $376.6M in FY2025 revenue, growing 20% year over year — faster than most Healthcare companies we track, at a -20.6% net margin.
Peers · Healthcare
Krystal Biotech, Inc.77B+Sonida Senior Living, Inc.64CCareDx, Inc78B+Arcutis Biotherapeutics, Inc.66BAtea Pharmaceuticals, Inc.47DMannKind Corporation69BNeighbors
San Mateo →Key facts
CEOEmily Marine Leproust
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersSouth San Francisco, CA
ExchangeNASDAQ: TWST
Employees979
IPO date2018-10-31
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.